XHXiaopeng Hu

Xiaopeng Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaopeng Hu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In Vitro Inhibition of Glyoxalase ? by Flavonoids: New Insights from Crystallographic Analysis

    by Hong Zhang, Jing Zhai, Liping Zhang, Cuiyun Li, Yining Zhao, Yunyun Chen, Qing Li, Xiao Peng Hu

    The antitumor pharmacological property of flavonoids is correlated with inhibition towards glyoxalase I (GLOI), a critical zinc-enzyme in the methylglyoxal detoxification pathway. In this study, 16 flavonoids were examined, and only baicalein (Ki of 0.183 µM) is identified as a potent in vitro GLOI inhibitor. X-ray crystallographic analysis reveals that baicalein chelates with the catalytic Zn2+ via its characteristic C6/C7 hydroxyl groups. The coordination ability of flavonoids, and therefore their ability to inhibit GLOI, is determined by the Zn2+ coordination geometry, the rigid skeleton of flavonoids and the geometry of the hydrophobic cavity of the GLOI active site. This structural basis could be useful in predicting GLOI inhibition of other natural polyphenols.


  • Open Access

    Structural basis for 18-β-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor

    by Hong Zhang, Qiang Huang, Jing Zhai, Yi-Ning Zhao, Li-Ping Zhang, Yun-Yun Chen, Ren-Wei Zhang, Qing Li, Xiao-Peng Hu

    Glyoxalase I (GLOI), a glutathione (GSH)-dependent enzyme, is overexpressed in tumor cells and related to multi-drug resistance in chemotherapy, making GLOI inhibitors as potential anti-tumor agents. But the most studied GSH analogs exhibit poor pharmacokinetic properties. The aim of this study was to discover novel non-GSH analog GLOI inhibitors and analyze their binding mechanisms. Mouse GLOI (mGLOI) was expressed in BL21 (DE3) pLysS after induction with isopropyl-β-D-1-thiogalactopyranoside and purified using AKTA FPLC system. An in vitro mGLOI enzyme assay was used to screen a small pool of compounds containing carboxyl groups. Crystal structure of the mGLOI-inhibitor complex was determined at 2.3 Å resolution. Molecular docking study was performed using Discovery Studio 2.5 software package. A natural compound 18-β-glycyrrhetinic acid (GA) and its derivative carbenoxolone were identified as potent competitive non-GSH analog mGLOI inhibitors with Ki values of 0.29 μmol/L and 0.93 μmol/L, respectively. Four pentacyclic triterpenes (ursolic acid, oleanolic acid, betulic acid and tripterine) showed weak activities (mGLOI inhibition ratio <25% at 10 μmol/L) and other three (maslinic acid, corosolic acid and madecassic acid) were inactive. The crystal structure of the mGLOI-GA complex showed that the carboxyl group of GA mimicked the γ-glutamyl residue of GSH by hydrogen bonding to the glutamyl sites (residues Arg38B, Asn104B and Arg123A) in the GSH binding site of mGLOI. The extensive van der Waals interactions between GA and the surrounding residues also contributed greatly to the binding of GA and mGLOI. This work demonstrates a carboxyl group to be an important functional feature of non-GSH analog GLOI inhibitors.


  • Structural Basis for the Inhibition of AKR1B10 by Caffeic Acid Phenethyl Ester (CAPE)

    by Liping Zhang, Hong Zhang, Xuehua Zheng, Yining Zhao, Shangke Chen, Yunyun Chen, Renwei Zhang, Qing Li, Xiaopeng Hu

    Caffeic acid phenethyl ester (CAPE), the major bioactive component of honeybee propolis, is a potent selective inhibitor of aldo-keto reductase family member 1B10 (AKR1B10), and a number of derivatives hold promise as potential anticancer agents. However, sequence homology between AKR1B10 and other members of the superfamily, including critical phase I metabolizing enzymes, has resulted in a concern over the selectivity of any potential therapeutic agent. To elucidate the binding mode of CAPE with AKR1B10 and to provide a tool for future in silico efforts towards identifying selective inhibitors, the crystal structure of AKR1B10 in complex with CAPE was determined. The observed interactions provide an explanation for the selectivity exhibited by CAPE for AKR1B10, and could be used to guide further derivative design.


  • Open Access

    Structural and biochemical characterization of fructose‐1,6/sedoheptulose‐1,7–bisphosphatase from the cyanobacterium Synechocystis strain 6803

    by Lingling Feng, Yao Sun, Hui Deng, Ding Li, Jian Wan, Xiaofeng Wang, Weiwei Wang, Xun Liao, Yanliang Ren, Xiaopeng Hu

    Cyanobacterial fructose–1,6/sedoheptulose‐1,7–bisphosphatase (cy–FBP/SBPase) plays a vital role in gluconeogenesis and in the photosynthetic carbon reduction pathway, and is thus a potential enzymatic target for inhibition of harmful cyanobacterial blooms. Here, we describe the crystal structure of cy–FBP/SBPase in complex with AMP and fructose‐1,6–bisphosphate (FBP). The allosteric inhibitor AMP and the substrate FBP exhibit an unusual binding mode when in complex with cy–FBP/SBPase. Binding mode analysis suggested that AMP bound to the allosteric sites near the interface across the up/down subunit pairs C1C4 and C2C3 in the center of the tetramer, while FBP binds opposite to the interface between the horizontal subunit pairs C1C2 or C3C4. We identified a series of residues important for FBP and AMP binding, and suggest formation of a disulfide linkage between Cys75 and Cys99. Further analysis indicates that cy–FBP/SBPase may be regulated through ligand binding and alteration of the structure of the enzyme complex. The interactions between ligands and cy–FBP/SBPase are different from those of ligand‐bound structures of other FBPase family members, and thus provide new insight into the molecular mechanisms of structure and catalysis of cy–FBP/SBPase. Our studies provide insight into the evolution of this enzyme family, and may help in the design of inhibitors aimed at preventing toxic cyanobacterial blooms.Database: Structural data have ben submitted to the Protein Data Bank under accession numbers 3ROJ and 3RPL.Structured digital cy-FBP/SBPase and cy-FBP/SBPase bind by x-ray crystallography (View interaction).


  • Zopolrestat as a Human Glyoxalase I Inhibitor and Its Structural Basis

    by Jing Zhai, Hong Zhang, Ligping Zhang, Yining Zhao, Sangke Chen, Yunyun Chen, Xinyu Peng, Qing Li, Minggui Yuan, Xiaopeng Hu


  • Partial Inhibition of Aldose Reductase by Nitazoxanide and Its Molecular Basis

    by Xuehua Zheng, Liping Zhang, Weijia Chen, Yunyun Chen, Wei Xie, Xiaopeng Hu

    A little is more than enough: Aldose reductase (AR) is a potential target in a wide range of diseases but its utility may be limited by the side effects caused by complete inhibition. Furthermore, known inhibitors of AR have suffered in clinical evaluation due to poor bioavailability. Here, the clinically used antiprotozoal drug nitazoxanide with proven bioavailability has been shown to partially inhibit AR, potentially circumventing the negatives effects of complete enzyme inhibition.


  • Open Access

    Crystallization and preliminary X-ray analysis of a novel halotolerant feruloyl esterase identified from a soil metagenomic library

    by Shang-Ke Chen, Kui Wang, Yuhuan Liu, Xiaopeng Hu

    Feruloyl esterase cleaves the ester linkage formed between ferulic acid and polysaccharides in plant cell walls and thus has wide potential industrial applications. A novel feruloyl esterase (EstF27) identified from a soil metagenomic library was crystallized and a complete data set was collected from a single cooled crystal using an in-house X-ray source. The crystal diffracted to 2.9 Å resolution and belonged to space groupP212121, with unit-cell parametersa= 94.35,b= 106.19,c= 188.51 Å, α = β = γ = 90.00°. A Matthews coefficient of 2.55 Å3 Da−1, with a corresponding solvent content of 51.84%, suggested the presence of ten protein subunits in the asymmetric unit.


  • Open Access

    Oxyresveratrol from Mulberry as a dihydrate

    by Hui Deng, Xixin He, Yujuan Xu, Xiaopeng Hu

    The title compound {systematic name: 4-[(E)-2-(3,5-dihy-droxy-phen-yl)ethen-yl]benzene-1,3-diol dihydrate}, C(14)H(12)O(4)·2H(2)O, a derivative of resveratrol, was isolated from mulberry. The linking C=C double bond has a trans conformation and allows the formation of a conjugated system throughout the mol-ecule. The dihedral angle between the benzene rings is 9.39 (9)°. In the crystal, mol-ecules are connected into a three-dimensional architecture through O-H⋯O hydrogen bonds between hy-droxy groups of oxyresveratrol and solvent water mol-ecules.


  • The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase

    by Xuehua Zheng, Liping Zhang, Jing Zhai, Yunyun Chen, Haibin Luo, Xiaopeng Hu

    Sulindac (SLD) exhibits both the highest inhibitory activity towards human aldose reductase (AR) among popular non‐steroidal anti‐inflammatory drugs and clear beneficial clinical effects on Type 2 diabetes. However, the molecular basis for these properties is unclear. Here, we report that SLD and its pharmacologically active/inactive metabolites, SLD sulfide and SLD sulfone, are equally effective as un‐competitive inhibitors of AR in vitro. Crystallographic analysis reveals that π–π stacking favored by the distinct scaffold of SLDs is pivotal to their high AR inhibitory activities. These results also suggest that SLD sulfone could be a potent lead compound for AR inhibition in vivo.


  • Crystallization and preliminary X-ray analysis of the RPB5 subunit of human RNA polymerase II

    by Xingyou Ye, Ping Xiao, Xiaowei Hu, Yunyun Chen, Liping Zhang, Wei Xie, Xiaopeng Hu

    RPB5 is an essential subunit of eukaryotic RNA polymerase II. It has been proposed to interact with DNA and several key transcription factors during transcription. These interactions are crucial for transcription and its regulation. Here, prior to obtaining complex structures of human RPB5 and its binding partners, recombinant human RPB5 was crystallized alone by vapour diffusion in hanging drops. A complete data set was collected from a single frozen crystal employing an in-house X-ray source. The crystal diffracted to 2.8 Å resolution and belonged to space group P43212. The likely Matthews coefficient and solvent content of 2.67 Å3 Da-1 and 53.92%, respectively, suggested the presence of two protein subunits in the asymmetric unit. The structure was solved using molecular replacement.